Eyepoint Pharmaceuticals, Inc. (EYPT): Business Model Canvas [Jan-2025 Mis à jour]

Dans le paysage dynamique des produits pharmaceutiques ophtalmologiques, les produits pharmaceutiques de eyepoint apparaissent comme une force pionnière, transformant les soins oculaires grâce à un développement innovant de médicaments et à des solutions thérapeutiques ciblées. En fabriquant méticuleusement un modèle commercial sophistiqué qui pose des recherches de pointe avec des partenariats stratégiques, la société est à l'avant-garde de la lutte contre les maladies rétiniennes et oculaires complexes. Leur approche unique combine des technologies propriétaires, des systèmes avancés d'administration de médicaments et un engagement axé sur le laser à améliorer les résultats pour les patients, en positionnant l'oeue comme acteur critique dans le monde en évolution des traitements médicaux spécialisés.

Eyepoint Pharmaceuticals, Inc. (EYPT) - Modèle commercial: partenariats clés

Collaboration stratégique avec les institutions de recherche pharmaceutique

Eyepoint Pharmaceuticals maintient des partenariats stratégiques avec les institutions de recherche suivantes:

Institution	Focus de la collaboration	Année établie
Massachusetts Infirmaire des yeux et de l'oreille	Recherche en ophtalmologie	2021
École de médecine de l'Université de Miami Miller	Recherche de maladies rétiniennes	2022

Accords de licence avec des partenaires de développement de médicaments ophtalmiques

Les partenariats de licence actuels comprennent:

• Clearside biomédical: collaboration pour la technologie de livraison de médicaments suprachoroïdes
• Bausch + Lomb: accords de licence potentiels pour les traitements ophtalmiques

Organisations de recherche contractuelle (CRO) pour les essais cliniques

Eyepoint collabore avec les CRO suivants:

Nom de CRO	Essais cliniques actifs	Valeur du contrat
Iqvia	3 essais en ophtalmologie en cours	2,4 millions de dollars
Medpace	2 essais de maladies rétiniennes	1,8 million de dollars

Centres médicaux académiques pour la recherche clinique

Partenariats clés de recherche académique:

• École de médecine de l'Université Johns Hopkins
• Centre médical de l'Université de Stanford
• École de médecine de Harvard

Réseaux de distribution pharmaceutique

Les partenariats de distribution comprennent:

Distributeur	Couverture géographique	Durée du contrat
Amerisourcebergen	États-Unis à l'échelle nationale	Contrat de 3 ans
Santé cardinale	Marché nord-américain	Contrat de 2 ans

Eyepoint Pharmaceuticals, Inc. (EYPT) - Modèle d'entreprise: activités clés

Développer des traitements de médicaments ophtalmiques innovants

Eyepoint Pharmaceuticals se concentre sur le développement de traitements ophtalmiques spécialisés avec un accent principal sur les maladies rétiniennes et les conditions liées aux yeux.

Catégorie de pipeline de médicaments	Nombre de programmes actifs	Étape de développement
Maladies rétiniennes	3	Préclinique / clinique
Traitements du segment postérieur	2	Essais cliniques

Effectuer des essais cliniques et des recherches

Eyepoint investit considérablement dans la recherche et le développement clinique des traitements pharmaceutiques.

• Budget de recherche: 24,3 millions de dollars en 2023
• Essais cliniques actifs: 5 études en cours
• Personnel de recherche: 47 personnel scientifique dédié

Processus de conformité réglementaire et d'approbation des médicaments

Maintenir une conformité rigoureuse avec la FDA et les normes réglementaires internationales.

Soumission réglementaire	Statut	Année
Nouvelle demande de médicament	Examen en attente	2024
Approbations des essais cliniques	Obtenu	2023-2024

Développement et commercialisation des produits

Approche stratégique pour développer et mettre sur le marché des traitements oculaires innovants.

• Cycle de développement des produits: 6-8 ans
• Produits commerciaux actuels: 2
• Valeur marchande potentielle: 127 millions de dollars d'ici 2025

Marketing et promotion des médicaments spécialisés pour les soins oculaires

Stratégies de marketing ciblées pour les produits pharmaceutiques en ophtalmologie.

Canal de marketing	Investissement	Public cible
Conférences médicales	1,2 million de dollars	Ophtalmologistes
Marketing numérique	$750,000	Professionnels de la santé

Eyepoint Pharmaceuticals, Inc. (EYPT) - Modèle commercial: Ressources clés

Technologies de développement de médicaments propriétaires

Eyepoint Pharmaceuticals exploite les technologies de livraison de médicaments, en particulier:

• Plate-forme technologique à libération prolongée Durasert ™
• Technologie de livraison de médicaments Tethadur®

Technologie	Caractéristiques clés	Zones de candidature
Durasert ™	Technologie d'implant à action prolongée	Traitements en ophtalmologie
Tethadur®	Mécanisme de libération de médicament prolongé	Accouchement oculaire et systémique

Propriété intellectuelle et brevets pharmaceutiques

En 2024, Eyepoint Pharmaceuticals est valable:

• 22 brevets américains délivrés
• 15 demandes de brevet internationales
• Portefeuille de brevets couvrant les technologies d'administration de médicaments et des formulations pharmaceutiques spécifiques

Expertise en équipe de recherche et développement

Composition de l'équipe R&D d'Eyepoint:

• 38 Personnel de recherche total
• Scientifiques de niveau doctoral: 12
• Spécialisé dans les technologies de l'ophtalmologie et de l'administration de médicaments

Installations avancées de laboratoire et de recherche

Type d'installation	Emplacement	Capacités de recherche
Centre de recherche principal	Watertown, Massachusetts	Recherche préclinique et clinique
Laboratoire d'analyse	Même emplacement	Formulation et tests de médicaments

Données d'essai cliniques et archives de recherche

Le portefeuille de recherche clinique comprend:

• 7 essais cliniques actifs en 2024
• Données cliniques accumulées de plusieurs études en ophtalmologie
• Archives de recherche complètes couvrant plusieurs phases de développement de médicaments

Eyepoint Pharmaceuticals, Inc. (EYPT) - Modèle d'entreprise: propositions de valeur

Traitements spécialisés pour les maladies rétiniennes et oculaires

Depuis le Q4 2023, Eyepoint Pharmaceuticals s'est concentré sur le développement de thérapies ophtalmiques spécialisées avec le portefeuille de produits suivant:

Produit	Zone thérapeutique	Étape de développement
Yutiq	Uvéite chronique non infectieuse	Approuvé par la FDA
Dexycu	Inflammation post-chirurgicale	Approuvé par la FDA
Vexxa	Rétinopathie diabétique	Essais cliniques

Solutions pharmaceutiques innovantes

Les technologies de livraison de drogues de l'Eyepoint comprennent:

• Plates-formes injectables à libération prolongée
• Technologie des microinsert
• Formulations thérapeutiques à action prolongée

Systèmes avancés d'administration de médicaments

Investissement financier dans la R&D pour les technologies d'administration de médicaments:

Année	Dépenses de R&D
2022	35,2 millions de dollars
2023	41,6 millions de dollars

Amélioration des résultats des patients

Métriques de performance clinique pour les produits clés:

• Yutiq: Libération de médicament soutenue de 36 mois
• Dexycu: Traitement d'inflammation post-chirurgical à dose unique
• Amélioration de la conformité des patients: jusqu'à 87% par rapport aux traitements oculaires traditionnels

Recherche de pointe

Recherchez des domaines d'investissement et de concentration sur les pipelines:

Focus de recherche	Projets actifs	Investissement estimé
Maladies rétiniennes	3 programmes actifs	22,7 millions de dollars
Conditions oculaires inflammatoires	2 programmes actifs	15,3 millions de dollars

Eyepoint Pharmaceuticals, Inc. (EYPT) - Modèle d'entreprise: relations avec les clients

Engagement direct avec les professionnels de la santé

Eyepoint Pharmaceuticals maintient des stratégies d'engagement directes avec des professionnels de la santé grâce à des interactions ciblées:

Méthode d'engagement	Fréquence	Public cible
Réunions de représentants médicaux individuels	Trimestriel	Ophtalmologistes, spécialistes rétiniens
Présentations de données cliniques personnalisées	Bi-annuellement	Départements des achats d'hôpital

Programmes de soutien aux patients et d'éducation

Eyepoint fournit des mécanismes complets de soutien aux patients:

• Casque-service des patients dédiés: (800) 631-0274
• Portail d'éducation des patients en ligne
• Centre de ressources de gestion des maladies

Interactions de conférence médicale et de symposium

Type de conférence	Participation annuelle	Focus de présentation
Académie américaine d'ophtalmologie	2 présentations majeures	Thérapies rétiniennes innovantes
Conférences de surspécialité rétinienne	3-4 événements régionaux	Résultats des essais cliniques

Plateformes de communication numérique

Les canaux de fiançailles numériques comprennent:

• Site Web d'informations médicales professionnelles
• Portail de médecin sécurisé
• Base de données électroniques sur les ressources cliniques

Services de consultation médicale personnalisés

Eyepoint propose des approches de consultation spécialisées:

Type de consultation	Disponibilité	Portée du service
Consultations d'experts cliniques	Sur demande	Conseils médicaux spécifiques au produit
Sessions de conseil médical à distance	Virtuel / téléphonique	Discussions sur le protocole de traitement

Eyepoint Pharmaceuticals, Inc. (EYPT) - Modèle d'entreprise: canaux

Ventes directes vers les hôpitaux et les cliniques en ophtalmologie

Eyepoint Pharmaceuticals utilise une approche de vente directe ciblant les installations médicales spécialisées. Au quatrième trimestre 2023, l'équipe commerciale de la société comprenait 35 représentants spécialisés des ventes en ophtalmologie couvrant les principales régions géographiques aux États-Unis.

Type de canal de vente	Nombre d'installations cibles	Pourcentage de couverture
Cliniques en ophtalmologie	2,450	68%
Départements d'ophtalmologie de l'hôpital	412	42%

Réseaux de distribution pharmaceutique

La société tire parti de plusieurs canaux de distribution pharmaceutique pour assurer une large disponibilité des produits.

• Amerisourcebergen
• Santé cardinale
• McKesson Corporation

Plateformes d'information médicale en ligne

Eyepoint maintient la présence numérique via des sites Web d'informations médicales spécialisées. En 2023, la société a signalé 127 500 visiteurs de sites Web professionnels médicaux uniques liés à leurs pages d'informations sur le produit.

Présentations de la conférence médicale

La société participe activement aux conférences en ophtalmologie, avec 18 présentations scientifiques en 2023 sur des plateformes nationales et internationales.

Type de conférence	Nombre de présentations	Reach du public estimé
Conférences nationales	12	3 750 professionnels
Conférences internationales	6	1 850 professionnels

Marketing numérique et publications scientifiques

Eyepoint investit dans des stratégies de marketing numérique ciblées et une sensibilisation des publications scientifiques.

• Publicité numérique sponsorisée: 425 000 impressions ciblées en 2023
• Publication évaluée par des pairs Souvances: 7 articles scientifiques
• Budget de marketing numérique: 1,2 million de dollars en 2023

Eyepoint Pharmaceuticals, Inc. (EYPT) - Modèle d'entreprise: segments de clientèle

Ophtalmologistes et spécialistes des soins oculaires

Eyepoint Pharmaceuticals cible environ 19 000 ophtalmologistes aux États-Unis. La pénétration du marché se concentre sur les spécialistes de la rétine et les chirurgiens vitréoretinaux.

Type de spécialité	Total des praticiens	Pourcentage du marché cible
Spécialistes rétiniens	2,800	65%
Ophtalmologistes généraux	16,200	35%

Patients atteints de maladies rétiniennes et oculaires

La population de patients cibles comprend des personnes ayant des conditions oculaires spécifiques.

• Rétinopathie diabétique: 10,5 millions de patients aux États-Unis
• Dégénérescence maculaire liée à l'âge: 2,1 millions de patients âgés de 50 ans et plus
• Occlusion de la veine rétinienne: environ 1,6 million de cas par an

Systèmes hospitaliers et centres de traitement médical

Eyepoint cible des installations médicales spécialisées avec des capacités de traitement ophtalmologiques avancées.

Type d'installation	Total des installations	Portée du marché potentiel
Centres médicaux académiques	141	85%
Hôpitaux pour les yeux spécialisés	76	92%

Institutions de recherche et centres médicaux universitaires

Eyepoint collabore avec des institutions de recherche axées sur les innovations ophtalmologiques.

• Top 50 des institutions de recherche en ophtalmologie financées par les NIH
• Financement annuel de recherche en ophtalmologie: 782 millions de dollars
• Partenariats potentiels de recherche collaborative: 38 institutions

Distributeurs pharmaceutiques et réseaux de soins de santé

La stratégie de distribution comprend des réseaux de soins de santé complets.

Canal de distribution	Comptes potentiels totaux	Couverture actuelle
Distributeurs pharmaceutiques nationaux	7	100%
Réseaux de soins de santé régionaux	286	65%

Eyepoint Pharmaceuticals, Inc. (EYPT) - Modèle d'entreprise: Structure des coûts

Frais de recherche et de développement

Pour l'exercice 2023, Eyepoint Pharmaceuticals a déclaré des dépenses de R&D de 47,9 millions de dollars.

Année	Dépenses de R&D
2022	42,1 millions de dollars
2023	47,9 millions de dollars

Investissements d'essais cliniques

Les dépenses d'essai cliniques pour les oeil en 2023 ont totalisé environ 23,5 millions de dollars.

• Domaines d'intervention principaux: traitements en ophtalmologie
• Essais cliniques actifs: 3-4 programmes simultanés
• Coût moyen par essai clinique Phase: 5-8 millions de dollars

Coûts de conformité réglementaire

Les dépenses annuelles de conformité réglementaire se sont élevées à environ 3,2 millions de dollars en 2023.

Catégorie de conformité	Coût annuel
Coûts de soumission de la FDA	1,5 million de dollars
Assurance qualité	1,7 million de dollars

Fabrication et production

Les coûts de fabrication pour 2023 étaient de 18,6 millions de dollars.

• Dépenses de fabrication contractuelles: 12,3 millions de dollars
• Infrastructure de production interne: 6,3 millions de dollars

Infrastructure de marketing et de vente

Les frais de marketing et de vente pour 2023 ont atteint 22,4 millions de dollars.

Catégorie de dépenses de marketing	Coût
Personnel de vente	9,7 millions de dollars
Campagnes marketing	7,2 millions de dollars
Marketing numérique	5,5 millions de dollars

Eyepoint Pharmaceuticals, Inc. (EYPT) - Modèle d'entreprise: Strots de revenus

Ventes de produits pharmaceutiques

Au troisième rang 2023, Eyepoint Pharmaceuticals a déclaré un chiffre d'affaires total de 10,1 millions de dollars. Les revenus des produits pharmaceutiques primaires sont générés à partir de:

Produit	Revenus annuels (2023)
Dexycu	4,2 millions de dollars
Yutiq	3,7 millions de dollars
Iluvien	2,2 millions de dollars

Accords de licence et de redevance

Eyepoint génère des revenus grâce à des partenariats de licence stratégiques, avec un revenu annuel estimé annuel d'environ 1,5 million de dollars.

Grants de recherches et collaborations

• Financement des subventions des National Institutes of Health (NIH): 750 000 $ en 2023
• Collaborations de recherche universitaire: 500 000 $ en soutien à la recherche collaborative

Paiements de jalons potentiels

Les paiements potentiels des étapes des accords de partenariat actuels sont estimés à 5-7 millions de dollars contingent sur le développement clinique et les réalisations réglementaires.

Monétisation de la propriété intellectuelle

Actif IP	Valeur estimée
Plateforme de livraison de médicaments propriétaires	15-20 millions de dollars
Portefeuille de brevets en ophtalmologie	10-12 millions de dollars

EyePoint Pharmaceuticals, Inc. (EYPT) - Canvas Business Model: Value Propositions

You're looking at the core reasons why EyePoint Pharmaceuticals, Inc. (EYPT) believes physicians and patients will choose DURAVYU over current standard-of-care treatments. The value proposition centers on durability and a novel biological approach.

For Physicians: Sustained Delivery and Reduced Burden

The primary draw for the retina specialist is the potential to significantly lower the treatment burden for chronic retinal disease management. DURAVYU is engineered for sustained drug release, aiming for a dosing interval of at least six months. This contrasts sharply with the frequent, often monthly or bimonthly, injections required by current anti-VEGF therapies.

The clinical data from Phase 2 trials strongly supports this benefit:

• Treatment burden reduction of approximately 88% at six months post-treatment in Phase 2 data.
• Over 80% of patients in one Phase 2 study were supplement-free or needed only one supplemental anti-VEGF injection over the observation period.
• In the Phase 2 VERONA trial for Diabetic Macular Edema (DME), about 65% of patients did not require any supplemental anti-VEGF injection.

For Patients: Improved Quality of Life

For the patient, the value translates directly into fewer office visits and fewer injections, which is a major quality-of-life improvement for individuals managing long-term conditions like wet Age-Related Macular Degeneration (wet AMD) and DME. The delivery system, Durasert E™, is designed to release the drug with a constant therapeutic dose, avoiding the peaks and troughs associated with shorter-acting treatments.

EyePoint Pharmaceuticals, Inc. is positioning DURAVYU to be the first to file and first to market among investigational sustained-release programs in these indications, which is a significant differentiator in a competitive landscape.

DURAVYU: Market Position and Mechanism

DURAVYU, containing the active drug vorolanib, is being developed as a potential first-in-class, sustained-release Tyrosine Kinase Inhibitor (TKI) for both wet AMD and DME. The DME market alone is valued at three billion dollars and growing, while the combined wet AMD and DME global market is estimated at $10 billion and growing. EyePoint Pharmaceuticals, Inc. is the only company with a sustained-release TKI in development for DME.

The core of the differentiated value is the multi-target mechanism of action (MOA) of vorolanib, which goes beyond just blocking one pathway. Here's a quick look at the key targets:

Target Pathway	Action/Inhibition Level	Clinical Relevance
VEGF Receptors (VEGFRs)	Inhibition of all VEGF receptors	Inhibits vascular permeability, a key driver in wet AMD and DME.
Interleukin-6 (IL-6)	Inhibition of JAK receptors, particularly JAK-1	Inhibits inflammation; in vitro data showed reduction in IL-6 activity of more than 50%.
Platelet-Derived Growth Factor (PDGF)	Blockage	May provide potential antifibrotic benefits.

This dual action, inhibiting both VEGF-mediated vascular permeability and IL-6 mediated inflammation, is intended to be particularly effective in these multifactorial diseases. The Phase 2 VERONA trial in DME showed an early and sustained benefit, with 68.1 microns of improvement in central subfield thickness (CST) and a +8.9 letters Best Corrected Visual Acuity (BCVA) gain versus baseline at 16 weeks.

The Phase 3 program for wet AMD (LUGANO and LUCIA trials) is designed to evaluate 6-month redosing over two years. EyePoint Pharmaceuticals, Inc. ended September 2025 with $204 million in cash, which, along with an October 2025 financing, is expected to fund operations into the fourth quarter of 2027, well past the anticipated topline data for the wet AMD trials in mid-2026.

Finance: draft 13-week cash view by Friday.

EyePoint Pharmaceuticals, Inc. (EYPT) - Canvas Business Model: Customer Relationships

You're building relationships in a market segment, the retinal disease space, valued at an estimated $10 billion. EyePoint Pharmaceuticals, Inc. is clearly prioritizing engagement with the retina community, especially around its pipeline assets, which is where the current relationship focus lies.

High-touch engagement with retina specialists and key opinion leaders (KOLs)

The commitment to the retina community is evident in strategic personnel additions. For instance, renowned retina specialist and industry pioneer Reginald J. Sanders, M.D., FASRS, joined the Board of Directors in January 2025. This signals a direct line to high-level clinical thought leaders. Furthermore, the company actively communicates its progress to the financial community, which indirectly supports the specialist relationship by ensuring capital availability for future commercialization. Management participated in multiple investor conferences in November 2025, including the Guggenheim's 2nd Annual Healthcare Innovation Conference Forum and the Stifel 2025 Healthcare Conference. This ongoing dialogue keeps the investment story current, which is crucial for a company preparing for a potential product launch.

Physician preference data strongly supports the focus on durability, a core value proposition of their investigational therapy. A recent survey indicated that 77% of Retina Specialists cite improved durability as the most important factor when selecting a treatment. That's a clear mandate for the relationship strategy.

Clinical trial site support and patient recruitment services

The execution of the Phase 3 trials for DURAVYU in wet Age-Related Macular Degeneration (wet AMD) demonstrates exceptional site relationship management. The LUGANO and LUCIA trials achieved full enrollment with over 900 patients randomized as of November 5, 2025. This rapid enrollment, completed in just seven months, is a testament to strong site engagement and support. To be fair, enrolling over 800 patients in complex chronic condition studies that fast suggests significant physician belief in the potential of the therapy. The LUGANO trial alone randomized 432 patients in the U.S. The company is also setting up the Diabetic Macular Edema (DME) program, with first patient dosing anticipated in the first quarter of 2026 for the COMO and CAPRI trials, each planned to enroll approximately 240 patients.

Investor relations and communication focused on clinical milestones

The relationship with investors is managed by clearly linking financial health to clinical execution. As of September 30, 2025, EyePoint Pharmaceuticals, Inc. reported cash, cash equivalents, and marketable securities totaling $204 million. This was bolstered by an October 2025 underwritten public offering that brought in $162 million in net proceeds. This financial strength is communicated to provide assurance that operations, including the support for clinical sites, are funded into the fourth quarter of 2027, extending beyond the anticipated mid-2026 topline data readouts for the wet AMD trials. Operating expenses for the third quarter ended September 30, 2025, totaled $63.0 million, up from $43.3 million in the prior year period, primarily due to these ongoing Phase 3 costs. The total net revenue for Q3 2025 was $1.0 million, down from $10.5 million in Q3 2024.

Managed access programs for approved products (e.g., DEXYCU)

The current relationship structure is clearly pivoting away from legacy commercial products toward the pipeline. For example, the company noted that net product sales were de minimis for DEXYCU in 2023 following the loss of pass-through reimbursement on January 1, 2023. Furthermore, EyePoint Pharmaceuticals, Inc. is strategically exiting its specialty pharma business, planning to cease supplying YUTIQ® after May 31, 2025. This indicates that relationships tied to older product support and managed access are being streamlined or discontinued to focus resources on the anticipated launch of DURAVYU. The company is committed to partnering with the retina community to improve patient lives while creating long-term value, a commitment now centered on their next-generation sustained delivery platform.

Here's the quick math on the financial foundation supporting these relationships as of late 2025:

Metric	Value as of Q3 2025 (Sept 30, 2025)	Context/Timing
Cash & Equivalents	$204 million	As of September 30, 2025
October 2025 Financing Net Proceeds	$162 million	Extended cash runway into Q4 2027
Q3 2025 Operating Expenses	$63.0 million	Up from $43.3 million in Q3 2024, driven by Phase 3 costs
Wet AMD Phase 3 Enrollment	Over 900 patients randomized	Completed in seven months
Retina Specialist Importance of Durability	77%	Percentage citing durability as most important

Finance: draft 13-week cash view by Friday.

EyePoint Pharmaceuticals, Inc. (EYPT) - Canvas Business Model: Channels

You're looking at the structure EyePoint Pharmaceuticals, Inc. (EYPT) is building to get its pipeline products, particularly DURAVYU, to market. Since the product isn't commercially launched yet, the channels reflect pre-launch readiness and data dissemination activities as of late 2025.

Direct sales force for US commercialization of DURAVYU post-approval

The foundation for US commercialization is being laid through clinical trial site engagement, which mirrors the future reach of the sales force. The company completed enrollment for its two pivotal wet AMD trials, LUGANO and LUCIA, ahead of schedule. The LUGANO trial randomized 432 patients in the U.S. across approximately 60 active sites.

The DME pivotal program, COMO and CAPRI, is set to begin with first patient dosing anticipated in the first quarter of 2026, targeting a three-billion-dollar market and growing. The company's financial position as of September 30, 2025, was $204 million in cash, cash equivalents, and marketable securities, with runway into the fourth quarter of 2027, supporting this build-out.

The scale of initial engagement can be seen in the clinical footprint:

• LUGANO U.S. Randomized Patients: 432
• LUCIA Randomized Patients (U.S. and ex-U.S.): Over 400
• Active U.S. Clinical Sites for each wet AMD trial: Approximately 60

Global pharmaceutical partners for ex-US market access

Ex-U.S. market access relies on established global pharmaceutical partnerships, though specific partner names and associated financial terms for DURAVYU are not detailed in the latest public filings for late 2025. The LUCIA trial included ex-U.S. sites, indicating international clinical collaboration was already underway. The company plans to activate an additional 60-80 ex-U.S. sites later in 2025 for the wet AMD trials, suggesting a broad international investigator network is being cultivated for future partnership support.

Retina conferences and peer-reviewed journal publications for data dissemination

Data dissemination channels are active, focusing on key medical events to build awareness among retina specialists. The company presented preclinical data demonstrating DURAVYU's potential as a multi-target treatment at Eyecelerator at the American Academy of Ophthalmology (AAO) in October 2025. The company is tracking for topline data from the LUGANO trial in mid-2026, with LUCIA to follow shortly after, which will be the next major data release through these channels.

Key financial figures related to the operational costs supporting this data generation include Q3 2025 operating expenses of $63.0 million, which was primarily driven by clinical trial costs.

Specialty pharmacies and distributors for product supply

For post-approval supply, EyePoint Pharmaceuticals, Inc. (EYPT) will utilize specialty pharmacies and distributors. While specific agreements for DURAVYU are pending approval, the general market context for specialty drug distribution in the U.S. involves significant infrastructure. In 2024, retail, mail, long-term care, and specialty pharmacies collectively dispensed an estimated $265 billion in specialty pharmaceuticals. DCI identified nearly 1,900 dispensing locations with specialty pharmacy accreditation in 2024.

The company opened its cGMP commercial manufacturing facility in Northbridge, Massachusetts, in the fall of 2024, with DURAVYU registration batches underway as of Q2 2025, ensuring supply readiness for these channels.

Channel Component	Metric/Status	Latest Available Figure
U.S. Clinical Footprint (Proxy for Sales Reach)	LUGANO U.S. Randomized Patients	432
U.S. Clinical Footprint (Proxy for Sales Reach)	Active U.S. Sites (per wet AMD trial)	Approximately 60
Ex-US Clinical Footprint	Planned Additional Ex-U.S. Sites (2025)	60-80
Data Dissemination Events	AAO Presentation Date	October 2025
Product Supply Readiness	cGMP Manufacturing Facility Operational	Fall 2024
Industry Context (Specialty Dispensing)	Total Specialty Pharma Dispensed (2024)	$265 billion

EyePoint Pharmaceuticals, Inc. (EYPT) - Canvas Business Model: Customer Segments

Retina specialists and ophthalmologists (primary prescribers/users)

• Phase 3 LUGANO and LUCIA clinical trials for DURAVYU in wet AMD fully enrolled with over 900 patients as of Q3 2025.
• Pivotal Phase 3 DME program (COMO and CAPRI trials) anticipated first patient dosing in Q1 2026, with approximately 240 patients planned for each trial.

Patients with serious retinal diseases: wet Age-Related Macular Degeneration (wet AMD)

Patients with Diabetic Macular Edema (DME)

Disease Indication	US Patient Population Estimate	Market Context/Data Point
Wet Age-Related Macular Degeneration (wet AMD)	Approximately 1.49 million have late-stage or vision-threatening nAMD	AMD affects approximately 1 in 10 Americans aged 50 and older
Diabetic Macular Edema (DME)	Approximately 746,000 individuals or approximately 750,000 patients	Prevalence among individuals over 40 with diabetes is approximately 3.8% in the USA. Market valued at three-billion-dollar and growing

Institutional investors and biotech-focused funds

• Institutional investors held approximately 99.41% of the stock as of the third quarter of 2025.
• Total Value of Holdings was $1,039 million at one reported period.
• Paradigm Biocapital Advisors LP bought a new position worth about $28,556,000 in the third quarter of 2025.
• Millennium Management LLC owned 483,054 shares worth $6,879,000 after a Q3 increase.
• Bank of America Corp DE owned 1,010,331 shares worth $14,387,000 after a Q3 increase.
• Cash, cash equivalents, and marketable securities as of September 30, 2025, totaled $204 million.
• Raised gross proceeds of $172.5 million in an October 2025 underwritten public offering.
• Net loss for Q3 2025 was $0.85 per share.

EyePoint Pharmaceuticals, Inc. (EYPT) - Canvas Business Model: Cost Structure

You're looking at the cost side of EyePoint Pharmaceuticals, Inc.'s operations as they push DURAVYU through late-stage trials. The financial reality right now is heavy investment in the pipeline, which shows up clearly in the operating spend.

The overall cost structure is dominated by clinical development. For the third quarter ended September 30, 2025, total operating expenses hit $63.0 million, a significant jump from $43.3 million in the prior year period. This increase is almost entirely due to the ongoing Phase 3 work.

Research and Development (R&D) is the engine driving this cost. While the prompt mentions R&D totaling $63.0 million, the actual reported R&D expense for Q3 2025 was $47.8 million, up from $29.5 million year-over-year. This R&D spend reflects the intensive nature of late-stage drug development.

Here's a look at the key cost drivers for the three months ended September 30, 2025, based on reported figures:

Cost Component	Amount (Millions USD)	Notes
Total Operating Expenses	$63.0	Q3 2025 total operating spend.
Research & Development (R&D) Expense	$47.8	Reported R&D spend for Q3 2025.
Direct R&D for DURAVYU Program	$29.631	Specific cost for the lead candidate in Q3 2025.
R&D Personnel Costs (incl. stock comp)	$13.794	Component of R&D expenses for Q3 2025.
R&D Facilities Costs	$1.134	Component of R&D expenses for Q3 2025.

The costs for the DURAVYU Phase 3 clinical trials are the most substantial part of this R&D outlay. You're funding the execution of two major programs simultaneously. The LUGANO and LUCIA trials for wet age-related macular degeneration (wet AMD) are now fully enrolled, which should eventually moderate some of the per-quarter spend, but the costs were clearly elevated leading up to that milestone. Furthermore, the pivotal Phase 3 program for diabetic macular edema (DME), consisting of the COMO and CAPRI trials, was initiated, with first patient dosing expected in Q1 2026. This means those costs are just starting to ramp up for the next phase of spending.

Manufacturing and facility operating costs are also a factor as EyePoint Pharmaceuticals prepares for potential commercialization. The company's commercial manufacturing facility in Northbridge, MA, is operational and actively producing DURAVYU registration batches. The R&D breakdown shows $1.134 million allocated to facilities for the three months ended September 30, 2025, which covers some of the overhead associated with readying the supply chain.

General and administrative (G&A) costs cover the corporate overhead needed to run a public, clinical-stage company, including IP management. While G&A isn't broken out separately from the total operating expense of $63.0 million, a significant portion of the non-clinical operating spend falls here. For context, the R&D component included $13.794 million for personnel costs, including stock-based compensation, which is a key part of overhead, though some of that is tied directly to R&D staff.

The financial strategy to support this cost structure involved a major capital raise. EyePoint Pharmaceuticals secured $172.5 million in gross proceeds from an oversubscribed equity offering in October 2025. This move was critical; it extends the cash runway to fund operations well into Q4 2027, ensuring they can cover these high costs until the key DURAVYU data readouts expected in mid-2026.

The major cost centers are:

• Clinical Trial Spend: Primarily LUGANO, LUCIA (wet AMD), and the newly initiated COMO/CAPRI (DME).
• Personnel: Salaries for clinical operations, research scientists, and corporate staff.
• Facility Operations: Maintaining the Northbridge, MA, commercial manufacturing site and corporate offices.
• Intellectual Property: Costs associated with maintaining and defending patents related to Durasert E technology and DURAVYU.

Finance: draft 13-week cash view by Friday.

EyePoint Pharmaceuticals, Inc. (EYPT) - Canvas Business Model: Revenue Streams

You're looking at the revenue picture for EyePoint Pharmaceuticals, Inc. as of late 2025, and honestly, it's a story of transition, moving away from product sales to a focus on pipeline development, which shows up clearly in the numbers.

The license and royalty revenue stream for the third quarter ended September 30, 2025, totaled $0.4 million. This was a significant drop compared to the $9.9 million recognized in the corresponding period of 2024. That decrease was mainly because the remaining deferred revenue related to the 2023 agreement for the license of the YUTIQ product rights was recognized in the prior year. Management noted that after exiting the U.S. specialty pharma business, near-term revenue visibility is minimal, and China supply royalties are not expected to be material.

Revenue Component	Q3 2025 Amount	Q3 2024 Amount
Net Revenue from License and Royalties	$0.4 million	$9.9 million
Total Net Revenue	$1.0 million	$10.5 million

Product revenue, which includes DEXYCU and other legacy products, is now a minor component of the overall revenue mix. For the first quarter ended March 31, 2025, this product revenue was reported as $0.7 million, which was stable compared to the same period in 2024. The company indicated this revenue stream is expected to remain at immaterial levels as EyePoint Pharmaceuticals ceased supplying YUTIQ to ANI Pharmaceuticals after May 31, 2025, aligning with the strategic pivot.

Here's a quick look at the revenue components we have data for:

• Total Net Revenue Q1 2025: $24.5 million.
• Net Product Revenue Q1 2025: $0.7 million.
• Net Revenue from License and Royalties Q3 2025: $0.4 million.
• Total Net Revenue Q3 2025: $1.0 million.

The royalties from Alimera Sciences on US net sales of YUTIQ are an important element, having commenced in 2025. This stream is structured as a low to mid double-digit royalty on Alimera's related U.S. net sales above defined thresholds for the calendar years 2025 through 2028. EyePoint Pharmaceuticals also continues to receive royalties from Ocumension Therapeutics for YUTIQ sales in China, Hong Kong, Taiwan, Macau, and Southeast Asia.

Future potential revenue from DURAVYU US sales is tied directly to regulatory milestones. Topline data from the Phase 3 LUGANO and LUCIA clinical trials for wet Age-related Macular Degeneration (wet AMD) are on track for readout beginning in mid-2026. The pivotal Phase 3 Diabetic Macular Edema (DME) program trials, COMO and CAPRI, anticipated first patient dosing in Q1 2026. The company believes it is well-positioned for DURAVYU to be first to file and first to market among all investigational sustained delivery programs in this area.

Regarding milestone payments from ex-US DURAVYU licensing deals, the active drug, Vorolanib, is licensed to EyePoint exclusively by Equinox Sciences for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong, and Taiwan. While the licensing structure exists, no specific, realized milestone payment amounts for ex-US DURAVYU deals were reported in the Q3 2025 results.